# SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer

> **NCT07697586** · PHASE2 · RECRUITING · sponsor: **Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.** · enrollment: 206 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** SKB264+SKB118

## Key facts

- **NCT ID:** NCT07697586
- **Lead sponsor:** Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-07
- **Primary completion:** 2028-08
- **Final completion:** 2029-08
- **Target enrollment:** 206 (ESTIMATED)
- **Last updated:** 2026-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697586, "SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*